GlycoMimetics Inc - Company Profile
Powered by 
All the data and insights you need on GlycoMimetics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date GlycoMimetics Inc Strategy Report
- Understand GlycoMimetics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Business Description
GlycoMimetics Inc (GlycoMimetics), is a late clinical-stage biotechnology company that discovers and develops novel glycomimetic therapeutics for the treatment of a range of diseases with unmet clinical needs.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
GlycoMimetics conducts research to advance its pipeline and pre-clinical pipeline candidates vaso-occlusive crisis associated with sickle cell disease, and venous thromboembolic disease. The company’s R&D programs also focus on advancing treatment options for relapsed or refractory acute myeloid leukemia; newly diagnosed fit AML-NCI (national cancer institute); other hematological cancers; inflammatory diseases; fibrosis and various other tumours. In FY2022, the company spent US$28.4 million on its R&D activities. The company owns issued patents that cover methods of use of rivipansel and has an issued patent which covers GMI-1359. The company also has several pending patent applications both in the US and in foreign countries covering uproleselan and its methods of use.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer